CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2016—Alere announced it has achieved in vitro diagnostic CE marking in Europe for its Alere Reader, a diagnostic analyzer that can be used in point-of-care and laboratory settings. The Alere Reader will be available initially for use with the Alere BinNow Legionella and Streptococcus pneumonia antigen cards, with other lateral flow applications and assays to follow.
After the test card is inserted into the analyzer, the Alere Reader detects, identifies, and analyzes the completed lateral flow assay. Results are displayed on an intuitive touchscreen and can be printed and linked to patient electronic medical records and back-end information systems. The Alere Reader will launch initially in Europe.
In a separate announcement, Alere will partner with health care technology company BioIQ to offer a seamless interface between BioIQ’s software platform, SoftSuite Dx, and the Alere Cholestech LDX System for immediate access to point-of-care lipid profile and glucose results for employee biometric screening events.
The partnership aims to facilitate the implementation of comprehensive, HIPAA-compliant biometric screening events and enhance the testing experience for employees by making the screening process, from scheduling to sample collection to tracking progress, readily available on smartphones and tablets through the SoftSuite Dx platform.
Alere, 781-647-3900